Listed

Beam Therapeutics Inc.: Form 10-Q for the period ended Sep 30, 2021

Filed with the SEC on Nov 8, 2021 and accepted by EDGAR at Nov 8, 2021, 08:31 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-07-01 to 2021-09-30$763.0kus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2021-01-01 to 2021-09-30$775.0kus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development3 months2021-07-01 to 2021-09-30$54.6mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2021-01-01 to 2021-09-30$290.3mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2021-07-01 to 2021-09-30−$69.6mus-gaap:OperatingIncomeLoss
Operating income9 months2021-01-01 to 2021-09-30−$329.0mus-gaap:OperatingIncomeLoss
Net income3 months2021-07-01 to 2021-09-30−$28.1mus-gaap:NetIncomeLoss
Net income9 months2021-01-01 to 2021-09-30−$305.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2021-07-01 to 2021-09-30−$0.42us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2021-01-01 to 2021-09-30−$4.86us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-07-01 to 2021-09-30−$0.42us-gaap:EarningsPerShareBasic
Basic EPS9 months2021-01-01 to 2021-09-30−$4.86us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-07-01 to 2021-09-3066,377,611 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2021-01-01 to 2021-09-3062,960,219 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2021-01-01 to 2021-09-30−$68.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2021-01-01 to 2021-09-30$33.4mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-09-30$612.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-09-30$941.4mus-gaap:AssetsCurrent
Total assetsAt period end2021-09-30$1.16bnus-gaap:Assets
Current liabilitiesAt period end2021-09-30$101.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-09-30$302.7mus-gaap:Liabilities
Shareholders' equityAt period end2021-09-30$853.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950170-21-003317. Last ingested by Listed: Nov 14, 2026, 12:58 ET. Listed shows no prices and gives no investment advice.